Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes

International Journal of Hematology

Volumn 65, Issue 4, 1997, Pages 339-354

  Geissler, R G ^a   Schulte, P ^a   Ganser, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cytokines; Erythropoietin; G CSF; IL 3; Myelodysplastic syndromes

Indexed keywords

CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 6; RETINOIC ACID; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; BONE PAIN; CHEILITIS; CLINICAL TRIAL; COLONY FORMING UNIT; DRY SKIN; ERYTHEMA; ERYTHROCYTE TRANSFUSION; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PANCYTOPENIA; PHLEBITIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0031172780     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(96)00562-2     Document Type: Review

References (161)

1. [1] Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol/Oncol Clin North Am 1992;6:607-618.
2. [2] Hoelzer D, Ganser A, Heimpel H. 'Atypical' leukemias: preleukemia, smoldering leukemia and hypoplastic leukemia. Rec Res Cancer Res 1984;93:69-101.
3. [3] Bennett JM, Catovsky D, Daniel M et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
4. [4] Delacretaz F, Schmidt PM, Piguet D et al. Histopathology and myelodysplastic syndromes: the FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987;87:180-189.
5. [5] Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (mds): new proposals. Br J Haematol 1995;91:612-617.
6. [6] Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol/Oncol Clin North Am 1992;6:557-570.
7. [7] Jacobs A. Genetic lesions in preleukemia. Leukemia 1991;5:277-282.
8. [8] Prchal JT, Trockmorton DW, Carrol AJ et al. A common progenitor for myeloid and lymphoid cells. Nature 1978;274:590-591.
9. [9] Raza A, Gezer S, Mundle S et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-276.
10. [10] Raza A, Mundle S, Iftikhar A et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995;48:143-154.
11. [11] Hirokawa M, Miura I, Miura AB. Two karyotypically unrelated clones with 5q-and 20q-in a primary myelodysplastic syndrome patient evolving into acute nonlymphocytic leukemia. Int J Hematol 1995;62:121-125.
12. [12] Van Lom K, Hagemeijer A, Smit E, Hahlen K, Groeneveld K, Löwenberg B. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia 1995;9:1818-1821.
13. [13] Kardos G, Veerman AJ, De Waal FC, Van Oudheusden LJ, Slater R. Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Med Pediatr Oncol 1996;26:54-56.
14. [14] Barnard DR, Kalousek DK, Wiersma SR et al. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: a report from the Children Cancer Group. Leukemia 1996;10:5-12.
15. [15] Völkers B, Ganser A, Greher J et al. Effect of tumor necrosis factor-alpha on human hematopoietic progenitor cells. Onkologie 1989;12:109-115.
16. [16] Verhoef GE, De Schouwer P, Ceuppens JL et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6:1268-1272.
17. [17] Hoefsloot LH, van Amelsvoort MP, Broeders CCAM et al. Impaired erythropoiesis in myelodysplastic syndrome is associated with the inability of erythropoietin receptor to activate STAT-5. Blood 1995;86(Suppl 1):271A.
18. [18] Aul C, Arning M, Runde V, Schneider W. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res 1991;15:571-575.
19. [19] Bowen DT, Jacobs A, Cotes MP et al. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1990;44:30-32.
20. [20] Jacobs A, Janowska-Wieczorek A, Caro J et al. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989;73:36-39.
21. [21] Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82:358-367.
22. [22] Blank J, Lange B. Preleukemia in children. J Pediatr 1981;98:565-569.
23. [23] Williamson PJ, Kruger AR, Reynolds PJ et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994;87:743-745.
24. [24] Mufti GJ, Galton DAG. Myelodysplastic syndromes. Natural history and features of prognostic significance. Clin Haematol 1986;15:953-978.
25. [25] Boogaerts MA. Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983;55:217-223.
26. [26] Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med 1991;90:338.
27. [27] Aul C, Schneider W. Myelodysplastic syndromes. A prognostic factor analysis of 221 untreated patients. Blut 1983;57:234-241.
28. [28] Kerkhofs H, Hermans I, Haak HL, Leeksma CHW. Utility of the FAB classification for myelodysplastic syndromes. Investigation of prognostic factors in 237 cases. Br J Haematol 1987;65:73-81.
29. [29] Mufti GJ, Stevens JR, Oscier DG et al. Myelodysplastic syndromes. A scoring system with prognostic significance. Br J Haematol 1985;59:425-431.
30. [30] Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-402.
31. [31] Tricot G, Vlietinck R, Boogaerts MA et al. Prognostic factors in the myelodysplastic syndromes. Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 1985;60:19-22.
32. [32] Varela GL, Chuang C, Woll JE, Bennett JM. Modifications in the classification of primary myelodysplastic syndromes. The addition of a scoring system. Haematol Oncol 1985;3:55-60.
33. [33] Ganser A, Ottmann OG, Schulz G et al. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study. Onkologie 1989;12:13-15.
34. [34] Ganser A, Seipelt G, Eder M et al. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 1992;19(Suppl 4):95-101.
35. [35] Ganser A, Heil G, Kolbe K et al. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia - initial results. Ann Hematol 1993;66:123-125.
36. [36] Ganser A, Seipelt G, Verbeeck W et al. Effect of combination therapy with all-trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994;8:369-375.
37. [37] Ganser A, Maurer A, Contzen C et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin, and x-tocopherol. Ann Hematol 1996;72:237-244.
38. [38] Löffler H, Schmilz N, Gassmann W. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol/Oncol Clin North Am 1992;6:619-632.
39. [39] Paquette RL, Koeffler HP. Differentiation therapy. Hematol/Oncol Clin North Am 1992;6:687-706.
40. [40] Pogliani EM, Baldicchi L, Pioltelli P, Miccolis IR, Mangiagalli M, Corneo GM. Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML). Leuk Lymphoma 1995;19:473-477.
41. [41] Anderson JE, Appelbaum FR, Fisher LD et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677-681.
42. [42] Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic bone marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996;14:220-226.
43. [43] Dührsen U, Hossfeld D. Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol 1994;69:213-221.
44. [44] Ganser A, Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol/ Oncol Clin North Am 1992;6:633-654.
45. [45] Ganser A. Hematopoietic growth factors in the treatment of myelodysplastic syndromes. Curr Opin Hematol 1995;2:204-209.
46. [46] Legare RD, Gilliland DG. Myelodysplastic syndrome. Curr Opin Hematol 1995;2:283-292.
47. [47] Löwenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-292.
48. [48] Negrin RS, Haeuber DH, Nagler A et al. Maintenance therapy of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 1990;76:36-43.
49. [49] Kobayashi Y, Okabe T, Ozawa K et al. Treatment of myelodysplastic syndromes with human granulocyte colony-stimulating factor: a preliminary report. Am J Med 1989;86:178-182.
50. [50] Negrin R, Haeuber DH, Nagler A et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I/II trial. Ann Intern Med 1989;110:976-984.
51. [51] Yuo A, Kitagawa S, Okabe T et al. Recombinant human granulocyte colony stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 1987;70:404-411.
52. [52] Greenberg P, Negrin R, Nagler A et al. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Int J Cell Cloning 1990;8(Suppl 1):293-302.
53. [53] Negrin RS, Stein R, Vardiman J et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor in combination with erythropoietin. Blood 1993;82:737-743.
54. [54] Yoshida Y, Hirashima K, Asano S et al. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991;78:378-384.
55. [55] Greenberg P, Taylor K, Larson R et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood 1993;82(Suppl 1):196a.
56. [56] Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 1993;82:1967-1974.
57. [57] Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndromes. J Clin Oncol 1993;11:1489-1496.
58. [58] Ohno R, Naoe T, Hirano M et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood 1993;81:1152-1154.
59. [59] Visani G, Cenacchi A, Tosi P et al. All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report. Br J Haematol 1992;81:444-448.
60. [60] Maurer AB, Ganser A, Seipelt G et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haematopoietic growth factors. Br J Haematol 1995;89:449-456.
61. [61] Estey EH, Kurzrock R, Talpaz M et al. Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 1991;77:291-295.
62. [62] Kurzrock R, Talpaz M, Gomez JA et al. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of lowover high-dose administration in selected patients. Br J Haematol 1991;78:352-358.
63. [63] Rose C, Wattel E, Bastion Y et al. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 1994;8:1458-1462.
64. [64] Schuster MW, Thompson JA, Larson R et al. Randomized phase II study of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS). Blood 1995;86(Suppl 1):338a.
65. [65] Delmer A, Karmochkine M, Cadiou M et al. Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndromes. Am J Hematol 1990;34:73-74.
66. [66] Antin JH, Smith BR, Holmes W et al. Phase I/II study of recombinant human granulocyte-macrophage colony stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988;72:705-713.
67. [67] Ganser A, Völkers B, Greher J et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes - a phase I/II trial. Blood 1989;73:31-37.
68. [68] Rosenfeld CS, Sulecki M, Evans C et al. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 1991;19:273-277.
69. [69] Thompson JA, Douglas JL, Kidd P et al. Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989;7:629-637.
70. [70] Vadhan-Raj S, Kellagher MJ, Keating M et al. Phase I study of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. N Engl J Med 1988;317:1545-1552.
71. [71] Wilson PA, Ayscue LH, Jones GR et al. Bone marrow histiocytic proliferation in association with colony-stimulating factor therapy. Am J Clin Pathol 1993;99:311-313.
72. [72] Maurer AB, Ganser A, Buhl R et al. Restoration of impaired cytokine secretion from patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 1993;7:189-195.
73. [73] Bhalla K, Birkhofer M, Arlin Z et al. Effect of recombinant GM-CSF and IL-3 on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988;2:810-813.
74. [74] Brach M, Klein H, Platzer E et al. Effect of interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 1990;18:748-753.
75. [75] Van der Lely N, De Witte T, Muus P et al. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol 1991;19:267-272.
76. [76] Gerhartz HH, Marcus R, Delmer A et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 1994;8:16-23.
77. [77] Höffken K, Overkamp F, Stirbu J et al. Recombinant human granulocyte macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie 1990;13:33-37.
78. [78] Hoelzer D, Ganser A, Ottmann OG et al. Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. Haematol Blood Transfusion 1990;33:763-769.
79. [79] Cheson BD, Simon R. Low dose ara-C in acute non-lymphocytic leukemia and myelodysplastic syndromes: a review of 20 years experience. Semin Oncol 1987;14(Suppl 1):126-133.
80. [80] Ganser A, Lindemann A, Seipelt G et al. The effect of recombinant human interleukin-3 in patients with normal hemopoiesis and in patients with secondary bone marrow failure. Blood 1990;76:666-676.
81. [81] Bernstein SF, Gilliland DG, Aster J et al. A randomized trial of two doses of recombinant interleukin-3 in patients with myelodysplastic syndrome. Blood 1992;80(Suppl. 1):410a.
82. [82] Dunbar CE, Smith D, Kimball J et al. Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia. Blood 1990;76(Suppl 1):141a.
83. [83] Ganser A, Seipelt G, Lindemann A et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990;76:455-462.
84. [84] Ganser A, Ottmann OG, Seipelt G et al. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993;7:696-701.
85. [85] Kurzrock R, Talpaz M, Estrov Z et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991;9:1241-1250.
86. [86] Nimer SD, Pacquette RL, Ireland P et al. A phase I/II study of the interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994;22:875-880.
87. [87] Seipelt G, Ganser A, Duranceyk H et al. Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. Ann Hematol 1994;68:167-170.
88. [88] Zwierzina H, Herold M, Geissler D et al. Soluble interleukin-2 (IL-2) receptor expression in patients with myelodysplastic syndromes is induced by granulocyte macrophage colony-stimulating factor and IL-3. Blood 1991;77:2795-2796.
89. [89] Seipelt G, Ganser A, Duranceyk H et al. Induction of TNF-x in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 1993;84:749-751.
90. [90] Gordon MS, Nemunaitis J, Hoffman R et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995;85:3066-3076.
91. [91] Toyhama K, Toyhama Y, Nakayama T, Ueda T, Nakamura T, Yoshida Y. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br J Haematol 1995;91:795-799.
92. [92] Bowen D, Ehmer B, Neubert P et al. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol 1991;19:613-616.
93. [93] Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:6771.
94. [94] Jensen PD, Heickendorff L, Pedersen B et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288-299.
95. [95] Hellström-Lindberg E, Birgegard G, Carlsson MD et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymph 1993;11:221-228.
96. [96] Imamura M, Kobayashi M, Kobayashi S et al. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 1994;68:163-166.
97. [97] Negrin RS, Stein R, Doherty K et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076-4081.
98. [98] Ghio R, Balleari E, Ballestrero A et al. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol 1993;90:58-64.
99. [99] Hansen PB, Hippe E, Hellström-Lindberg E et al. Recombinant human granulocyte macrophage colony-stimulating factor plus erythropoietin may improve anemia in selected patients with myelodysplasia. Am J Hematol 1993;44:229-236.
100. [100] List AL, Noyes W, Power J et al. Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin-3 (IL-3) and erythropoietin (EPO). Blood 1993;82(Suppl 1):377a.
101. [101] Verhoef G, Demuynck H, Zachäe P et al. Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin-3 and erythropoietin. Blood 1993;82(Suppl 1):377a.
102. [102] Nand S, Sosman J, Godwin JE et al. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994;83:357-360.
103. [103] Ganser A, Lindemann A, Ottmann OG et al. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis. Blood 1992;79:2583-2591.
104. [104] Dombret H, Chastang C, Fenaux P et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995;332:1678-1683.
105. [105] Ohno R, Tomonaga M, Kobayashi T et al. Effect of granulocyte-colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871-877.
106. [106] Rowe JM, Andersen J, Mazza J et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients ( > 55 to 70 years of age) with acute myelogenous leukemia. A study of the Eastern Cooperative Oncology Group (E 1490). Blood 1995;86:457-462.
107. [107] Stone R, Berg DT, George SL et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671-1677.
108. [108] Demuynck H, Delforge M, Verhoef GEG et al. Feasability of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 1996;92:351-359.
109. [109] Delforge M, Demuynck H, Vandenberghe P et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995;86:3660-3667.
110. [110] Estey EH, Thall P, Andreef M et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-678.
111. [111] Bernell P, Kimby E, Hast R. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 1994;8:1631-1639.
112. [112] Broxmeyer HE, Cooper S, Williams DE et al. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1988;16:594-602.
113. [113] Vadhan-Raj S, Broxmeyer HE, Spitzer G et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood 1989;74:1491-1498.
114. [114] Ottmann OG, Ganser A, Seipelt G et al. Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 1990;76:1494-1502.
115. [115] Rafanelli D, Grossi A, Longo G et al. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 1992;6:323-327.
116. [116] Schouten HC, Vellenga E, van Rhenen DJ et al. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 1991;5:432-436.
117. [117] Van Kamp H, Tineke C, Prinsze-Postema TC et al. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 1991;78:488-493.
118. [118] Masters GS, Baines P, Tang C, Bowen D, Burnett AK. Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS). Leuk Res 1995;19:561-566.
119. [119] Verbeek W, Vehmeyer K, Wörmann B, Hiddemann W. The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes. J Cancer Res Clin Oncol 1995;121:338-342.
120. [120] Piacibello W, Sanavio F, Bresso P et al. Stem cell factor improvement of proliferation and maintenance of hematopoietic progenitors in myelodysplastic syndromes. Leukemia 1994;8:250-257.
121. [121] Asano H, Ohashi H, Ichihara M et al. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 1994;84:588-594.
122. [122] Asano H, Hotta T, Ichihara M, Murate T, Kobayashi M, Saito H. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes. Leukemia 1994;8:833-838.
123. [123] Glinsman-Gibson B, Spier C, Baier M, Taetle R, Broudy VC, List AF. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. Leukemia 1994;8:827-832.
124. [124] Soligo D, Servida F, Cortelezzi A et al. Effects of recombinant human stem cell factor (rh-SCF) on colony formation and long-term bone marrow cultures (LTBMC) in patients with myelodysplastic syndromes. Eur J Haematol 1994;52:53-60.
125. [125] Wu HK, Chiba S, Hirai H, Takaku F, Yazaki Y. Effect of stem cell factor (c-kit ligand) on clonogenic leukemic precursor cells: synergy with other hematopoietic growth factors. Am J Hematol 1994;47:328-330.
126. [126] Verhoef G, Van Den Berghe H, Boogaerts M. Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hematopoietic growth factors. Leukemia 1992;6:766-769.
127. [127] Ganser A, Janssen JWG, Ottmann OG et al. In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukemia 1991;5:487-492.
128. [128] Anastasi J, Feng J, LeBeau MM et al. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy and clonal expansion. Blood 1993;81:1580-1585.
129. [129] Ohyashiki K, Ohyashiki JH, Toyama K et al. Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor. Jpn J Cancer Res 1989;80:848-854.
130. [130] Kaczmarski RS, Mufti GJ. Lowdose filgrastim therapy for chronic neutropenia. N Engl J Med 1993;329:1280-1281.
131. [131] Herrmann F, Lindemann A, Klein H et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989;3:335-338.
132. [132] Willemze R, Visani G, de Witte Th et al. A randomized phase I/II study with recombinant human GMCSF in patients (pts) with myelodysplastic syndromes at a relatively low risk of developing acute leukemia. Blood 1990;76(Suppl 1):337a.
133. [133] Gradishar WJ, LeBeau MM, O'Laughlin R et al. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood 1992;80:2463-2470.
134. [134] Takahasha M, Yoshida Y, Kaku K et al. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol 1993;89:189-194.
135. [135] Yoshida Y, Nakahata T, Shibata A et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. Leuk Lymph 1995;18:457-463.
136. [136] Bessho M, Jinnai I, Matsuda A et al. Improvement of anemia by recombinant human erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Clon 1990;8:445-458.
137. [137] Oster W, Krumwieh D, Brune T et al. Evaluation of erythropoietin (EPO) in the treatment of patients with myelodysplastic syndromes (MDS) - preclinical data supporting a rationale for sequential therapy with granulocyte-macrophage colony stimulating factor (GM-CSF) and EPO. J Cancer Clin Oncol 1990;116(Suppl):280.
138. [138] Stebler C, Ticheili A, Dazzi H et al. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol 1990;18:1204-1208.
139. [139] Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991;77:419-423.
140. [140] Hellström E, Birgegard G, Locker D et al. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 1991;47:355-360.
141. [141] Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991;78:1658-1663.
142. [142] Laporte JPN, Isnard F, Fenaux P. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes. Contrib Nephrol 1991;88:271-272.
143. [143] Kurzrock R, Talpaz M, Estey E et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 1991;5:985-990.
144. [144] Verhoef GE, Zachee P, Ferrant A et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol 1992;64:16-21.
145. [145] Shepherd JD, Currie CJ, Sparling TG et al. Erythropoietin therapy of myelodysplastic syndromes. Blood 1992;79:1891-1892.
146. [146] Cazzola M, Ponchio L, Beguin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: results of a phase I/II clinical trial. Blood 1992;79:29-37.
147. [147] Goy A, Belanger C, Casadevall N et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 1993;84:232-237.
148. [148] Ludwig H, Fritz E, Leitgeb C et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993;4:161-167.
149. [149] Depaoli L, Levis A, Isabella N et al. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant-human-erythropoietin in myelodysplastic syndromes. Haematologica 1993; 78:118-122.
150. [150] Yoshida Y, Anzai N, Kawabata H et al. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Ann Hematol 1993;66:175-180.
151. [151] Zeigler ZR, Jones D, Rosenfeld CS et al. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells 1993;11:49-55.
152. [152] Stenke L, Wallvik J, Celsing F et al. Prediction of response to treatment with recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993;7:1324-1327.
153. [153] Urabe A, Mizoguchi H, Takaku F et al. Phase II clinical study of recombinant erythropoietin on the anemia of myelodysplastic syndrome. Rinsho Ketsueko 1993;4: 928-936.
154. [154] Shapiro S, Gershon H, Rosenbaum H et al. Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin. Leukemia 1993;7:1328-1333.
155. [155] Mittelman M. Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers. Acta Haematol 1993;90:53-57.
156. [156] Razzano M, Caslini C, Cortellazzo S et al. Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1992;81:628-630.
157. [157] Spiriti MAA, Petti MC, Latagliata R et al. Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile? Leuk Lymph 1993;9:79-83.
158. [158] Mohr B, Herrmann R, Huhn D. Recombinant human erythropoietin in patients with myelodysplastic syndromes and myelofibrosis. Acta Haematol 1993;90:65-70.
159. [159] Isnard F, Najman A, Jaar B et al. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymph 1994;12:307-314.
160. [160] Stone RM, Bernstein SH, Demetri G et al. Treatment with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Leuk Res 1994;18:769-776.
161. [161] Rose EH, Abels RI, Nelson RA et al. The use of r-HuEpo in the treatment of anemia related to myelodysplasia (MDS). Br J Haematol 1995;89:831-837.